Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials

N/A

SAT0392 Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of A Phase 3, Randomized, Controlled Trial

10.1136/annrheumdis-2014-eular.4419 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 736.1-736 ◽

Author(s):

F. Zhang ◽

T. Tencer ◽

S. Li

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Work Productivity ◽

Phase 3 ◽

Productivity Improvement ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

SAT0568 Long-Term Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Analysis of 3 Phase 3 Studies

10.1136/annrheumdis-2015-eular.3590 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 866.2-866 ◽

Cited By ~ 2

Author(s):

F. Zhang ◽

Z. Clancy ◽

S. Li

Keyword(s):

Psoriatic Arthritis ◽

Work Productivity ◽

Pooled Analysis ◽

Phase 3 ◽

Productivity Improvement ◽

Phosphodiesterase 4 ◽

The Targeted Oral, Once-Daily Phosphodiesterase 4 Inhibitor Roflumilast and the Leukotriene Receptor Antagonist Montelukast Do Not Exhibit Significant Pharmacokinetic Interactions

The Journal of Clinical Pharmacology ◽

10.1177/0091270008330980 ◽

2009 ◽

Vol 49 (4) ◽

pp. 389-397 ◽

Cited By ~ 12

Author(s):

Gabriele M. Böhmer ◽

Nassr Nassr ◽

Marcus Wenger ◽

Andreas Hünnemeyer ◽

Gezim Lahu ◽

...

Keyword(s):

Receptor Antagonist ◽

Leukotriene Receptor Antagonist ◽

Once Daily ◽

Phosphodiesterase 4 ◽

Pharmacokinetic Interactions ◽

Leukotriene Receptor ◽

A Novel Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor, Crisaborole Ointment, Reduced Pruritus and Signs of Atopic Dermatitis in 2 Phase 3 Studies in Children and Adults

10.1542/peds.141.1_meetingabstract.251 ◽

2018 ◽

Author(s):

Adelaide A. Hebert ◽

Lawrence F. Eichenfield ◽

Mark G. Lebwohl ◽

Amy S. Paller ◽

Eric L. Simpson ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Anti Inflammatory ◽

LB0001 Long-Term (52-Week) Results of a Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis

10.1136/annrheumdis-2013-eular.526 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A163-A163 ◽

Cited By ~ 5

Author(s):

A. Kavanaugh ◽

P. J. Mease ◽

A. O. Adebajo ◽

J. Wollenhaupt ◽

C. Hu ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

SAT0402 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pharmacodynamic Results of A Phase 3, Randomized, Controlled Trial (PALACE 1)

10.1136/annrheumdis-2014-eular.3878 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 739.4-740 ◽

Author(s):

P. Schafer ◽

P. Chen ◽

L. Fang ◽

A. Wang ◽

R. Chopra

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

078. LONG-TERM WORK PRODUCTIVITY IMPROVEMENT ASSOCIATED WITH APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF THREE PHASE 3 STUDIES

Rheumatology ◽

10.1093/rheumatology/kex062.078 ◽

2017 ◽

Vol 56 (suppl_2) ◽

Author(s):

Frank Zhang ◽

Zoe Clancy ◽

Stan Li ◽

Farhan Mughal

Keyword(s):

Psoriatic Arthritis ◽

Work Productivity ◽

Pooled Analysis ◽

Phase 3 ◽

Productivity Improvement ◽

Phosphodiesterase 4 ◽

Three Phase ◽

SAT0377 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial

10.1136/annrheumdis-2014-eular.1575 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 730.2-730 ◽

Author(s):

A. Adebajo ◽

A. Wells ◽

C. Edwards ◽

A. Kivitz ◽

P. Bird ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phase 3 Studies Treating Children and Adult Patients with Mild to Moderate Atopic Dermatitis with Crisaborole Ointment, a Novel, Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor

10.1542/peds.141.1_meetingabstract.275 ◽

2018 ◽

Author(s):

Amy S. Paller ◽

Wynnis L. Tom ◽

Mark G. Lebwohl ◽

Mark Boguniewicz ◽

Lawrence F. Eichenfield ◽

...

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Anti Inflammatory ◽

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2014.01.682 ◽

2014 ◽

Vol 70 (5) ◽

pp. AB164 ◽

Keyword(s):

Controlled Trial ◽

Severe Psoriasis ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽